Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2011. The report details a specific share repurchase transaction executed on April 13, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes related to a share buyback.
- Shares Purchased: 500,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,250 pence per share; lowest price paid was 1,235 pence per share.
- Treasury Holdings: Following cancellation, the Company holds 493,224,284 shares in Treasury.
- Treasury Percentage: Represents 8.71% of total issued share capital and 9.55% of total voting rights.
- Shares in Issue: 5,166,313,079 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the Company's issued share capital through the purchase and subsequent cancellation of 500,000 shares. This transaction increased the proportion of Treasury shares held by the Company relative to total voting rights.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,166,313,079) for calculating disclosure thresholds under FSA rules.
- Confirm the updated Treasury share count (493,224,284) and its impact on voting rights (9.55%).
- Note that this filing does not contain financial performance data; refer to Form 20-F for comprehensive financial results.